Chemotherapy Resistance in B-ALL with Cryptic NUP214-ABL1 Is Amenable to Kinase Inhibition and Immunotherapy

BCR-ABL1 kinase inhibitors have improved the prognosis of Philadelphia-chromosome-positive (Ph(+))-acute lymphoblastic leukemia (ALL). Ph-like (or BCR-ABL1-like) ALL does not express BCR-ABL1 but commonly harbors other genomic alterations of signaling molecules that may be amenable to therapy. Here,...

Descripción completa

Detalles Bibliográficos
Autores principales: Nardi, Valentina, McAfee, Steven L, Dal Cin, Paola, Tsai, Harrison K, Amrein, Philip C, Hobbs, Gabriela S, Brunner, Andrew M, Narayan, Rupa, Foster, Julia, Fathi, Amir T, Hock, Hanno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Precision Medicine Clinic: Molecular Tumor Board
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8895729/
https://www.ncbi.nlm.nih.gov/pubmed/35641210
http://dx.doi.org/10.1093/oncolo/oyab052

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8895729/
https://www.ncbi.nlm.nih.gov/pubmed/35641210
http://dx.doi.org/10.1093/oncolo/oyab052

Ejemplares similares